Skip to contentD
Decoy Therapeutics Inc.
D
DCOYDecoy Therapeutics Inc. Q2 2021 · 10-Q
Revenue$571.39K$571.39K−54.0% vs Q2 2020 Net Income-$3.07M-$3.07MN/M vs Q2 2020 EPS Diluted-$0.07-$0.07N/M vs Q2 2020 Operating Income-$3,116,820N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Decoy Therapeutics Inc. · CIK 1615219 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-545.5%−392.6 pt vs Q2 2020
Net margin-538.1%−394.5 pt vs Q2 2020
ended Jun 30, 2021 · filed Aug 5, 2021 · 36 d after period end